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The Coronavirus Disease 2019 (COVID-19) has already caused hundreds of thousands of
deaths worldwide in a few months. Cardiovascular disease, hypertension, diabetes and
chronic lung disease have been identified as the main COVID-19 comorbidities. Moreover,
despite similar infection rates between men and women, the most severe course of the
disease is higher in elderly and co-morbid male patients. Therefore, the occurrence of
specific comorbidities associated with renin–angiotensin system (RAS) imbalance
mediated by the interaction between angiotensin-converting enzyme 2 (ACE2) and
desintegrin and metalloproteinase domain 17 (ADAM17), along with specific genetic
factors mainly associated with type II transmembrane serine protease (TMPRSS2)
expression, could be decisive for the clinical outcome of COVID-19. Indeed, the
exacerbated ADAM17—mediated ACE2, TNF-a, and IL-6R secretion emerges as a
possible underlying mechanism for the acute inflammatory immune response and the
activation of the coagulation cascade. Therefore, in this review, we focus on the main
pathophysiological aspects of ACE2, ADAM17, and TMPRSS2 host proteins in COVID-
19. Additionally, we discuss a possible mechanism to explain the deleterious effect of
ADAM17 and TMPRSS2 over-activation in the COVID-19 outcome.
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The Severe Acute Respiratory Syndrome Coronavirus Virus 2 (SARS-CoV-2), which first appeared in
Wuhan, Hubei province, China (1, 2), spread rapidly around the world, leading to a pandemic scenario
and causing thousands of deaths (2). The higher mortality and morbidity rates in coronavirus disease 19
(COVID-19) are associated with comorbidities, such as cardiovascular disease, pulmonary hypertension,
diabetes, liver, and kidney diseases (3). An important bias, found in several studies conducted in different
countries, is that the most severe course of the disease occurs mainly in elderly male individuals, despite
similar infection rates between men and women (4–6). Curiously this disease sex bias has also been
observed in SARS-CoV and MERS outbreaks (7, 8), highlighting similarities in the pathogenic
mechanisms between these viruses (9). These observations provide significant indications of a
possible genetic predisposition to the viral infection and the severity of the disease.org October 2020 | Volume 11 | Article 5767451
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related to the interplay between the angiotensin-converting
enzyme 2 (ACE2), desintegrin and metalloproteinase domain
17 (ADAM17) and the type II transmembrane serine protease
(TMPRSS2) in the major clinical disorders reported in COVID-
19 patients.SARS-COV-2 INFECTION
The coronavirus surface spike (S) protein mediates the entry of
SARS-CoV-2 into the target cells by binding to ACE2 and the
subsequent fusion of the viral envelope with the host cell
membrane (10, 11). After binding of SARS-S to ACE2, the
S-protein undergoes a proteolytic cleavage between the S1 and
S2 subunits by the TMPRSS2 serine protease (12–14).
Alternatively, another less important pathway involves
cathepsin L, a pH-dependent endo-lysosomal host cell
protease, after uptake of virions into target cell endosomes
(15). Entry through the non-endosomal pathway is more
efficient than the endosomal pathway, showing the greater
relevance of the protease-dependent cleavage (16). However,
data from an in vitro experiment blocking the two proteases
suggest the involvement of an additional protease (17). The furin
protease emerges as a likely candidate, since the SARS-CoV-2 S-
protein contains four redundant furin cleavage sites that are
absent in the SARS-CoV (18). In addition, the new coronavirus
has an S1/S2 cleavage site (RRARSVAS) similar to a host furin-
cleavable peptide in epithelial sodium channel a-subunit (ENaC-
a) (19). Moreover, sequence-based prediction studies suggest a
more efficient cleavage of the SARS-CoV-2 than the SARS-CoV
S-protein by furin (18, 20). These differential characteristics may
explain the higher SARS-CoV-2 infectivity. However, Xia and
colleagues have recently demonstrated, in an in vitro assay using
293T cells, that furin cleavage sites might not be very relevant for
SARS-CoV-2 infections in human airway (21). In addition, a
neutrophil elastase (NE) cleavage site near the S1–S2 protein was
recently identified in the A2a SARS-CoV-2 subtype (D614G
mutation), suggesting an important role of neutrophil elastase in
the infection (22). Therefore, the possible participation of other
proteases in the viral entry requires further investigation.ACE2/ADAM17 IN COVID-19’S
COMORBIDITIES
ACE2 is a type I transmembrane, endothelium-bound
carboxymonopeptidase protein, and ubiquitously expressed in
endothelial cells of several organs, with the highest levels in the
cardiovascular system, intestine, kidneys, brain, testicles and lungs
(23). The ACE2 gene is located on the X-chromosome and is highly
polymorphic (24). Due to its genomic location, ACE2 expression
could be affected by parental imprinting and X-inactivation in
females, resulting in different ACE2 expression levels and renin
activation between females and males (25, 26). Furthermore, theFrontiers in Immunology | www.frontiersin.org 2possible involvement of ACE2-related genetic factors in the
pathogenesis of COVID-19 has been supported by the
identification of polymorphic markers in the ACE2 locus and
present in patients with specific comorbidities related to the
severity of COVID-19 (5, 27, 28).
The ACE2 molecule, besides being a receptor of SARS-CoV and
SARS-CoV-2 (29–32), reduces the activity of the renin–angiotensin
system (RAS) by converting angiotensin (Ang) I and Ang II into
Ang 1-9 and Ang 1-7 respectively (33–35). Thus, the ACE2 protein
has been shown to play an important role in protecting against
some disorders such as cardiovascular complications, chronic
obstructive pulmonary disease (COPD) and diabetes, among
other COVID-19 comorbidities (36). The ACE2/Ang 1-7 axis
counterbalances the ACE/Ang II-I axis by decreasing Ang II
levels, the activation of angiotensin type 1 receptors (AT1Rs) and,
thus, leads to decreased pathophysiological effects on tissues, such as
inflammation and fibrosis (37). Furthermore, it is important to note
that the difference in ACE2 expression levels also depend on factors
such as age and lifestyle. There are evidences that ACE2 activity
differs between males and females (38), with males having higher
levels in the lungs (39). Recent studies have shown an increase in
plasma levels of the soluble form of ACE2 (sACE2) with age, being
higher in men than in women (40). This increase was interpreted, in
some cases, as a consequence of an increased activity of ADAM17-
sheddase (will be discussed below). Moreover, using public gene
expression datasets, a differential expression was found not only for
ACE2 but also for the TMPRSS2 gene in the nasal and bronchial
airways in relation to age (41). Interestingly, it was found a higher
TMPRSS2 expression on nasal epithelial cells from Black individuals
than Asian, Latino, andWhite individuals (42). These finding could
explain the 2–3 times higher incidence of COVID-19 among Black
individuals (43).
Children have shown significantly lower expression of both
SARS-CoV-2 receptors in the upper and lower airways (41).
Regarding ACE2 activity, some studies have shown that ACE2
activity is lower in older women than in young ones, while the
same does not occur in males (38, 44). These findings indicated
that the regulation of ACE2 expression may be the result of a
process dependent on both age and gender, and may be related to
the pathological progression and poor prognosis of COVID-
19 (45).
As far as lifestyle is concerned, two habits seem to have a
significant effect on ACE2: cigarette smoking and diet. The
former has been shown to decrease ACE2 blood levels (45),
leading to an imbalance in RAS homeostasis (46). On the other
hand, Smith and colleagues showed that cigarette smoking
causes a dose-dependent upregulation of ACE2 both in rodent
and human lungs (47). These findings were recently confirmed
by Sharif-Askariboth and colleagues, who observed a significant
ACE2 upregulation in the nasal and bronchial airways of
smokers compared to non-smokers (41). Two systematic
reviews by Zhao et al. and Vardavas & Nikitara, indicate that
smoking is indeed a risk factor in COVID-19 (48, 49).
Apparently, nicotine promotes ACE2 overexpression through
the alpha7-nicotinic receptor (50). However, there are many
other substances in cigarette smoke that promote respiratory andOctober 2020 | Volume 11 | Article 576745
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hand, considering that the expression of ACE2 may promote
protection against pulmonary and cardiovascular damage, it is
plausible to think that both functions of ACE2 may play a role in
COVID-19, however, at different times of the infection process
and with different impact. Diet has been associated with the
modulation of ACE2 expression and its activity. Indeed, salt rich
diets tend to increase ACE2 activity (51) and the rate of ACE/
ACE2 in the glomeruli (52), while glucose rich diets may
decrease ACE2 leading to an imbalance between ACE/ACE2 in
the heart (53).
Concerning to ADAM17 proteinase, it is expressed by several
tissues, such as muscle, lungs, placenta, ovaries, testicles,
pancreas, kidney, small intestine, thymus, and heart (54). As a
membrane “sheddase” protease, ADAM17 removes the
membrane protein ectodomains (sheddase activity). The
mechanisms by which ADAM17 is regulated have not yet been
fully elucidated, but would depend on the stimulus and the cell
type. Specifically, in the ADAM17-mediated shedding of the
soluble active TNF-a form and of the epidermal growth factor
receptor (EGFR), the participation of iRhom2, a proteolytically
inactive member of the rhomboid family, proved to be important
for maturation and substrate specificity of ADAM17 (55). On the
other hand, ADAM17 activity could be induced by apoptosis,
Ca2+ ionophores, fibroblast growth factor 7 (FGF7), protein
kinase C (PKC) activators and purine 2 (P2) receptor agonists
(56–59). In addition, ADAM17 can also be activated in response
to pathogen infection through Toll-like receptors (60, 61) and
may involve the translocation of phosphatidylserine (PtdSer) to
the outer cell membrane leaflet, a crucial step for ADAM17 to
exert its “sheddase” activity (62).
ACE2/ADAM17 in Cardiovascular Disease
In the human and animal model of cardiovascular disease and
hypertension, an increase in the ACE/AC2 ratio has been
reported, as a consequence of an increased downregulation of
ACE2 expression (63–65). Moreover, the activity of the soluble
form of ACE2 (sACE2) is increased in patients with heart failure
(HF) and correlates with the severity of the disease (65–67). The
relevance of RAS unbalance in cardiovascular diseases has been
highlighted by a recent study of Sama and colleagues (67). In this
study, men with heart failure had higher ACE2 plasma levels
than women in the same condition. Thus, increased ACE2
plasma levels have been interpreted as a molecular marker of a
poor prognosis. These authors did not find an association
between the use of ACE inhibitors and angiotensin receptor
blockers (ARBs) with higher plasma ACE2 concentration plasma
levels (67). These findings suggest that the use of ACE2 inhibitors
and ARBs would not increase the vulnerability to a poor clinical
outcome in patients with COVID-19. Finally, and based on the
impact of the use of ACE inhibitors, AT1Rs blockers and
mineralocorticoid receptor antagonists, the higher plasma
levels of ACE2 have been interpreted as a consequence of the
higher activity of ADAM17 (68). In support of this
interpretation, elevated levels of TNF-a have been found in
patients with heart disease, such as myocarditis, and were
negatively correlated with left ventricular systolic functionFrontiers in Immunology | www.frontiersin.org 3(69).The increased expression of ADAM17 was reported in
peripheral blood mononuclear cells (PBMC) in patients with
congestive heart failure, as well as in malignant recurrent
ventricular arrhythmia after acute myocardial infarction (70,
71). Moreover, the increased expression of ADAM17, as well
as of TNF-a was associated with rupture of atherosclerotic
coronary plaques in patients with myocardial infarction (72).
Finally, ADAM17 knockdown inhibited hypertension-induced
cardiac hypertrophy and fibrosis (73).
In summary, several lines of evidence support that low
expression levels of the ACE2 membrane form (mACE2) and
higher ADAM17 activity would be associated with cardiovascular
disease. In the context of SARS-CoV-2 infection this condition
would be even more exacerbated as a consequence of a molecular
mechanism triggered by SARS-CoV-2 infection (74), thus
explaining the higher incidence of COVID-19 in these kind of
patients (68).
ACE2/ADAM17 in Pulmonary Disease
ACE2 has protective effects in the lungs (63). ACE2 knockout
results in a pathology similar to the acute respiratory distress
syndrome (ARDS) in mice (75), and ACE2 polymorphisms have
been correlated with the ARDS severity (29). Moreover, ACE2
has been shown to protect mice with acute lung disease by SARS-
CoV infection (76). In this study genetic evidence confirmed that
ACE2 is a crucial SARS-CoV receptor in vivo, and that the Spike
protein of the SARS-CoV reduces ACE2 expression. These
results provided a molecular explanation of why SARS-CoV
infections cause severe and often lethal lung failure and suggest
a rational for the use of an ACE2 replacement as therapy.
Among the lung diseases associated with the most severe clinical
picture of COVID-19 are chronic obstructive pulmonary disease
(COPD) and cystic fibrosis (CF) (77). COPD is characterized by
emphysema, chronic bronchitis and irreversible airflow obstruction
due to airway inflammation. Analysis of transcriptomic data of
biopsies from COPD patients have shown a significantly
upregulation of ACE2 gene expression when compared with
healthy subjects. These results are correlated with the upregulated
ACE2 gene expression in the lung tissues of smokers compared to
healthy individuals (41). In addition, the modulation of the
ADAM17 and EGF receptor (EGFR) axis is another important
factor involved in COPD and CF, to maintain the balance between
anti and pro inflammatory processes and excessive tissue
regeneration and remodeling. Indeed, the EGFR/ADAM17
signaling pathway can exercise anti- and pro- inflammatory
functions, depending on stimuli, substrate and cell type (78). In
this sense, pathogens as virus and bacteria can activate the
ADAM17/EGFR signaling pathway through Toll-like receivers
(TLR) (60, 61). The ADAM17/EGFR - mediated pro-
inflammatory response is mediated by the neutrophil chemotactic
factor CXCL8 (79), and the anti-inflammatory response through the
shedding of TNF receptor type 2 (TNFR2). Furthermore, Stolarczyk
and colleagues (80) showed a higher ADAM17 mediated, pro-
inflammatory molecules secretion, such as CXCL8, the IL6 cytokine
receptor (IL6R) and growth factor amphiregulin (AREG) in airway
epithelial cells from COPD patients by cigarette smoke (CS). The
subsequently activation of interleukin receptor gp130 and EGFROctober 2020 | Volume 11 | Article 576745
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collagen deposition. Therefore, the reduction of ADAM17 and
EGFR activity may contribute to anti-inflammation and tissue
remodeling in COPD (80). Finally, these data may explain why
patients with COPD infected by SARS-CoV-2 are more susceptible
to progress towards severe symptoms of COVID-19 (81).
ACE2/ADAM17 in Diabetes and
Renal Diseases
Both ACE2 and ADAM17 have functions associated with
glycemic homeostasis. ACE2 modulates insulin secretion
from pancreatic b-cells and the growth of pancreatic islet
cells (63). In addition, studies have demonstrated the
protective role of ACE2 against pancreatic dysfunction in
diabetes and that ACE2 is related to diabetic nephropathy
(DN) (63). On the other hand, the increased activity of
ADAM17 has been correlated with increased insulin
resistance and hyperglycemia (82, 83). Furthermore, the
upregulation of ADAM17 activity exacerbated tissue damage
in DN (84) and increased insulin receptor resistance in patients
with type 2 diabetes (85, 86). In addition, insulin treatment has
been shown to attenuate renal secretion of ADAM17 and ACE2
in diabetic mice, suggesting that tubular renal secretion of
ACE2 could be mediated by ADAM17 in diabetes-induced
type 1 nephropathy.
ACE2 has a protective effect through the regulation of RAS
(87), and plays a crucial role in the pathogenesis of renal diseases,
decreasing levels in acute kidney injury and chronic renal disease
induced by hypertension and diabetes (88). In this context, the
worse clinical outcome observed in COVID-19 patients with
diabetes may be due to the exacerbated decline in ACE2 induced
by the up-regulation of ADAM17 as consequence of SARS-
CoV-2 infection.
Renal dysfunction is one of the most serious complications in
patients with COVID-19 (81) with a high risk of mortality. ACE2,
TMPRSS2, and cathepsin L are highly expressed and active in the
kidney (89, 90). In retrospective, postmortem tissue studies from
COVID-19 patients detected SARS-CoV-2 viral load in the
kidney, with preference in glomerular cells and tubules.
Moreover, SARS-CoV-2 infection more frequently induced
acute renal failure in elderly patients with comorbidities such as
hypertension and heart failure (90, 91).ACE2/ADAM17/TMPRSS2 INTERPLAY
IN COVID-19
ACE2 plays an important role in SARS-CoV-2 infection not only
in viral entry (30–32), but also in providing protection against
acute cardiovascular and pulmonary injury and protection against
DIC caused by COVID-19 (37, 92, 93). After interaction with the
viral S-protein, ACE2 is internalized along with viral particles into
endosomes, reducing surface tissue expression of ACE2.
Interestingly, after SARS-CoV infection of myocardial and lung
tissues, the ACE2 mRNA expression is also inhibited (76, 94, 95).Frontiers in Immunology | www.frontiersin.org 4On the other hand, the ADAM17 activity is up-regulated by the
internalization of SARS-CoV–ACE2 in the ACE2 cytoplasmic
dependent manner (74). The ADAM17 up-regulation leads to
the ACE2 ectodomain proteolytic cleavage (65, 96, 97). Curiously,
the ACE2 tail as well as ADAM17 expression proved to be
necessary for SARS-CoV infection. However, the underlying
mechanism by which the interaction of the S/ACE2 proteins
mediates ADAM17 activation is not yet clear, nor how
ADAM17 facilitates viral entry. Probably, the protease activity of
ADAM17 might be important for the fusion of viral particles with
the cytoplasmic membrane. Finally, the increased activity of the
ADAM17 sheddase may also lead to the cleavage of TNF-a and
IL6R and other pro-inflammatory molecules, reinforcing the
inflammatory process during SARS-CoV-2 infection (37, 98).
ACE2 can also be cleaved by the TMPRSS2 protease (97).
TMPRSS2-mediated ACE2 cytoplasmic tail cleavage may lead to
an increased viral uptake and processing through a cathepsin L-
dependent pathway (97).
In this context, it is important to highlight that the
internalization of ACE2 can trigger positive feedback harmful to
tissues. The ACE2 downmodulation would lead to an increase in
Ang II level and the activation of the A1T receptor, which in turn
would activate ADAM17 more. Therefore, the exacerbated
reduction of ACE2 is, indirectly, responsible for its own cleavage
by ADAM17 and, consequently, for the depletion of ACE2 in the
tissue and release of the sACE2 form (68). The sACE2 and mACE2
are composed by extracellular and membrane bound domains of
ACE2, respectively. Additionally, the ACE2 expression could also be
transcriptionally downmodulated as a consequence of AT1Rs
activation (99). Indeed, tissue downregulation of ACE2 mediated
by the SARS-CoV-2 infection reduces the protective effects of ACE2
in various organs such as kidneys, heart, lungs and gut through Ang
1-7 which counteracts the Ang II effects (34, 36, 100). The beneficial
effects of recombinant ACE2 administration on human pulmonary
arterial hypertension (101) and in lung lesions caused by viral
infections (102, 103), support the relevance of sACE2 in blocking
viral particles in preventing the interaction with transmembrane
ACE2. The marked reduction of ACE2 expression on the cell
surface causes an imbalance in the RAS system, leading to an
increase in Ang II plasma levels, which in turn promote thrombosis,
through a thrombin-dependent pathway (104). Ang II does not just
act as a vasoconstrictor but also as a pro-inflammatory molecule
through AT1R (105). Indeed, the Ang II-AT1R axis activates
ADAM17 which in turn releases the mature form of EGFR, the
soluble form of IL-6Ra (sIL-6Ra) and TNF-a (105, 106). On the
other hand, endothelial cells infection and activation of
macrophages in the pulmonary alveoli are the main source of
pro-inflammatory cytokines such as IL-1b, IL-6, IFN-g, IL-8, and
TNF-a triggering the acute inflammatory response, known as
“cytokine storm” (107, 108). These inflammatory infiltrates in the
alveolar lumen release toxic molecules leading to diffuse alveolar
damage, pulmonary edema and fibrin deposition in the alveolar
space (109). Moreover, endothelial injury has also been associated
with elevated plasma level of von Willebrand factor (vWF),
neutrophils and macrophages infiltrate (110). Afterwards,
activated neutrophils secrete neuthrophil extracellular trapsOctober 2020 | Volume 11 | Article 576745
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both the extrinsic and intrinsic pathway (111). Finally, the
prothrombotic state could be facilitated by hypoxia-inducible
factor (HIF) after lung injury (112).ACE2/ADAM17/TMPRSS2 UNDERLYING
RISK FACTORS FOR COVID-19
The involvement of ACE2 in the pathophysiology of COVID-19
has become a “conundrum” that needs to be unraveled. While
ACE2 is the viral receptor for SARS-CoV-2, it also provides
protection against the harmful effects of RAS-mediated
activation by viral infection (37). Moreover, as mentioned
above, strong evidences indicate that the expression of ACE2
would be subject to mechanisms of hormonal, genetic and age-
related regulations (5, 40, 113, 114).
Several data support the involvement of an increased activity
of ADAM17 in both COVID-19`s comorbidities and SARS-
CoV-2 infection: i) increased plasma levels of ACE2 soluble form
(sACE2) with age in men (40, 41); ii) higher expression levels of
sACE2 in men, with heart failure, than woman as a consequence
of increased ADAM17 activity (67); and iii) higher ACE2 level
expression and up-regulated activity of ADAM17 in patients
with chronic pulmonary inflammation (54), COPD (41, 80),
diabetes (82, 83) and renal diseases (86). These findings support
the epidemiological data showing a higher incidence and severity
of COVID-19 in elderly men with comorbidities (115) than in
healthy young men or women (4, 6). In fact, while the rate of fatal
cases in patients without comorbidities is approximately 0.9%, it
is much higher for patients with COVID19’s comorbidities:
specifically, cardiovascular disease (10.5%), diabetes (7.3%),
and hypertension (6.3%) (116).Frontiers in Immunology | www.frontiersin.org 5In this context, a key factor to understand this apparent
paradox in the pathophysiology of COVID-19, related to the
conflicting evidences ACE2’s role, could be found in the delicate
interplay balance between the cleavage of ACE2 by both
ADAM17 and TMPRSS2 proteases in a stepwise fashion.
At the initial infection stage, the high mACE2 expression
levels in nasal and bronchial airways and lung in patients with
some comorbidities or harmful lifestyles for COVID-19 may be a
critical risk factor for higher infection levels (41, 69, 117).
Posteriorly, and as a consequence of the high viral infection
level, the expression of ACE2 and its mRNA would be greatly
diminished in these patients. Moreover, the SARS-S/ACE2
interaction would trigger the ACE2 cytoplasmic tail alteration,
which would induce ADAM17 activation and viral entry (Figure
1). On the other hand, the increased expression of IL-1b, as a
consequence of the inflammatory process induced by SARS-
CoV-2 infection, may also contribute to the over-activation of
ADAM17 in the early stage of the infection (118).
At a later stage, the SARS-S/ACE2 mediated up-regulation of
ADAM17 in pulmonary and cardiac tissues may exacerbate the
imbalance in RAS, already present in patients with risk diseases in a
looping harmful feedback manner, thus becoming the main
responsible for the worst clinical outcome. The exacerbated up-
regulation of ADAM17-mediated ACE2 cleavage would lead to two
additional harmful effects: i) prevent the premature infected cells death
by superinfection-mediated apoptosis, before viral particles release; ii)
preclude the virus locking mediated by the interaction with surface
ACE2 during viral budding. It is important to emphasize that virus-
mediated receptor down-modulation strategies to optimize viral
infectivity are used by other viruses, such as HIV-1 (119, 120),
influenza, measles and pulmonary SARS-CoV (76) (Figure 1).
Another important mechanism to take into account, in this
complex pathophysiological equation, is the ACE2 cytoplasmicFIGURE 1 | Pathophysiological consequences of ADAM17 over-activation in SARS-CoV-2 infection. After the binding of SARS-S to ACE2, the S-protein undergoes
a proteolytic cleavage by TMPRSS2, and the virus enters the host cell. The attachment of the S protein to ACE2 triggers ADAM17 activation, increasing mACE2
downmodulation, reducing surface ACE2 expression. The increased ADAM17-mediated ACE2 shedding exacerbates the imbalance of RAS, in a looping feedback
manner and increases inflammation by TNF-a the IL6 cytokine receptor (IL6R) and growth factor amphiregulin (AREG) cleavage. Finally, the sACE2 release by
ADAM17 cleavage might block the viral particles entry.October 2020 | Volume 11 | Article 576745
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ACE2 tail by TMPRSS2 increases viral uptake in target cells and,
therefore, TMPRSS2 could promote SARS-CoV-2 entry by two
mechanisms: i) by SARS-S cleavage, which activates the S protein
for membrane fusion, and ii) by ACE2 cleavage, which might
promote viral uptake through the cathepsin L-dependent
pathway, which would then infect the cell by fusing with the
endosomal membrane (97) (Figure 2).
Although TMPRSS2 and ADAM17 share the same specificity
for ACE2, important differences can be observed in the cleavage
of ACE2 (97). First, the fractions generated by the cleavage of
these proteases have different molecular sizes due to different
cleavage sites. Second, the ACE2 ectodomain released by the
cleavage by ADAM17 is shed into the extracellular medium, as
sACE2 biologic active form. However, the TMPRRS2-mediated
ACE2 cleavage would not release the ACE2 ectodomain; instead,
a C-terminal intracellular cleavage fragment was observed, at
least as demonstrated by in vitro experiments (97) (Figure 2).
Therefore, the differences in the cleavage sites and its biological
consequences may be critical. Indeed, only the sACE2 form
would exert a protective effect, blocking circulating viral particles
(76) (Figure 1). In short, although the cytoplasmic tail cleavage
of ACE2 by TMPRSS2 and ADAM17 act synergistically
unprotecting the pulmonary and cardiac tissue against the
harmful effects of RAS activation, only the TMPRSS2-mediated
cleavage would not release the ACE2 soluble active forms. Thus,
the TMPRSS2 - mediated ACE2 cleavage would be more harmfulFrontiers in Immunology | www.frontiersin.org 6to the host. However, it is still unknown whether ACE2 cleavage
by both proteases is mutually exclusive or not, and the relevance
of the interplay of these mechanisms on the pathophysiology of
COVID-19. In this scenario, it can be expected that increased
expression of TMPRSS2 induced by androgen hormones or the
occurrence of specific genetic variants (5, 42, 121), or both
factors together, may lead to exacerbate, even more, the ACE2
cleavage—mediated harmful effects, by decreasing the
membrane-bound or soluble biologically active ACE2 forms.
This hypothesis may explain the higher incidence in men
than in women or in certain races (5, 42, 121). More recently, a
specific SARS-CoV-2 A2a subtype—mediated TMPRSS2 and
MX1 genes up-regulation has been described in European and
North American populations (22). These findings along with the
higher TMPRSS2 expression on nasal epithelial cells from Black
individuals than others races, may explain the higher rates of
infection, and worse COVID-19 clinical outcomes observed in
these populations, by the increasing TMPRSS2-mediated SARS-
CoV-2 and ACE2 cleavage.
In this context, it is plausible to assume that the medical history
of COVID-19 patients, in terms of comorbidities, sex, age, race and
specific life style associated with high mACE2 expression levels in
the upper airways and lung, may be a risk factor for higher infection
levels at the first stage of the infection. Subsequently, an exacerbated
decrease in the membrane-bound active ACE2 form, both for
ADAM17 and TMPRSS2 over-activation, and for the infection
itself, may exacerbate the RAS imbalance (ACE/ACE2) in patientsFIGURE 2 | Pathophysiological consequences of TMPRSS2—mediated ACE2 cleavage in SARS-CoV-2 infection. The TMPRSS2-mediated ACE2 cleavage
promotes viral uptake through the cathepsin L-dependent pathway, inactivates the ACE2 membrane-bound form leaving the tissue unprotected against detrimental
effect of RAS activation and does not release the soluble blocking form of ACE2.October 2020 | Volume 11 | Article 576745
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hypertension, diabetes and chronic lung disease. Finally, the over-
activation of TMPRSS2 in elderly and co-morbid male patients may
be decisive for the clinical outcome, leading to an acute setting
rather than a moderate clinical outcome. Therefore, over-activation
of ADAM17 and TMPRSS2 could be the main mechanism
underlying the negative effects of RAS imbalance, acute
inflammation and intravascular coagulation observed in elderly
males with COVID-19 comorbidities.CONCLUDING REMARKS
In the context of the current pandemic, it is a priority to gain a
detailed understanding of the molecular mechanisms involved in the
pathophysiology of COVID-19 in order to identify risk factors and
develop new effective therapeutic approaches. The evidence presented
in this review highlights the deleterious effect of ACE2
downmodulation by ADAM17 and TMPRSS2 in COVID-19
pathogenesis. The delicate balance between ACE2, ADAM17, and
TMPRSS2 interactions in each specific pathophysiological condition
appears as a critical key factor. Therefore, the occurrence of specificFrontiers in Immunology | www.frontiersin.org 7comorbidities associated with RAS imbalance mediated by ACE2/
ADAM17 along with specific genetic factors mainly associated with
TMPRSS2 expression could be decisive for the clinical outcome of
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